IMPAX Laboratories, Inc. Confirms Patent Challenge Relating to INTUNIVTM, 4 mg

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of patents listed by Shire Development Inc. in connection with INTUNIVTM (guanfacine hydrochloride), 4 mg.